Larimar Therapeutics公司股价在盘前交易中大幅上涨35.6%，此前该公司宣布其针对一种神经疾病的治疗药物获得了美国食品药品监督管理局（FDA）的“突破性疗法”认定。这一认定通常意味着该药物在早期临床研究中显示出显著优势，有望加速其后续的开发和审评进程。
Larimar Therapeutics公司股价在盘前交易中大幅上涨35.6%，此前该公司宣布其针对一种神经疾病的治疗药物获得了美国食品药品监督管理局（FDA）的“突破性疗法”认定。这一认定通常意味着该药物在早期临床研究中显示出显著优势，有望加速其后续的开发和审评进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.